Financials Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 18:00:00 29/11/2024 GMT			5-day change	1st Jan Change
7.070 ^USD	+10.82%		+24.04%	-28.30%

11-20	Recursion Pharmaceuticals, Exscientia Complete Business Combination	MT
11-20	Recursion Pharmaceuticals, Inc. - Special Call

Projected Income Statement: Recursion Pharmaceuticals, Inc.

income-statement-evolution-chart RECURSION-PHARMACEUTICALS

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	3.962	10.18	39.84	44.58	70	76.01	99.45
Change	-	156.89%	291.46%	11.88%	57.04%	8.58%	30.84%
EBITDA ¹	-	-174.4	-234	-325.7	-410.9	-514.7	-515.5
Change	-	-	34.18%	39.19%	-26.19%	-25.24%	-0.17%
EBIT ¹	-	-182.8	-245.7	-350.1	-410.7	-501.1	-455
Change	-	-	34.44%	42.46%	-17.33%	-22%	9.2%
Interest Paid ¹	-	-2.952	6.251	-0.097	-0.4	-1.6	-
Earnings before Tax (EBT) ¹	-	-186.5	-239.5	-332.1	-392	-484	-347
Change	-	-	28.42%	38.69%	-18.03%	-23.47%	28.31%
Net income ¹	-87.01	-186.5	-239.5	-328.1	-411.2	-498.3	-347
Change	-	114.33%	28.42%	36.99%	-25.34%	-21.17%	30.36%
Announcement Date	03/03/21	23/03/22	27/02/23	27/02/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3
Net sales ¹	2.562	2.549	2.534	2.533	5.333	7.674	13.16	13.68	12.13	11.02	10.53	10.89	13.79	14.42	26.08	18.17	12.98	12.22	14.68	20.83	5	5	35
Change	-	-0.51%	-0.59%	-0.04%	110.54%	43.9%	71.49%	3.92%	-11.28%	-9.21%	-4.39%	3.4%	26.66%	4.52%	80.91%	-30.33%	-28.6%	-5.78%	20.04%	41.96%	-76%	0%	600%
EBITDA ¹	-	-	-	-	-	-	-59.58	-	-66.14	-76.17	-	-91.38	-88.96	-91.58	-91.16	-191.3	-207.9	-211.8	-184	-192.7	-	-	-
Change	-	-	-	-	-	-	-	-100%	-	15.17%	-100%	-	-2.64%	2.94%	-0.46%	-109.86%	-8.68%	-1.88%	13.13%	-4.73%	100%	-	-
EBIT ¹	-30.48	-40.93	-46.4	-64.96	-55.98	-66.19	-62.57	-60.98	-69.86	-81.72	-99.55	-98.93	-96.34	-100.5	-98.35	-123.2	-135.9	-139.5	-135	-131	-108.7	-110.8	-82.9
Change	-	34.26%	13.37%	39.99%	-13.82%	18.24%	-5.47%	-2.54%	14.57%	16.96%	21.83%	-0.62%	-2.62%	4.36%	-2.18%	-25.23%	-10.31%	-2.67%	3.21%	2.96%	17.02%	-1.93%	25.18%
Charge d'intérêts ¹	-0.249	-2.501	-0.17	-	-	-	-	-	-	-	-	-0.097	-	-	-	-0.4	-0.4	-0.4	-0.4	-0.4	-	-	-
Earnings before Tax (EBT) ¹	-30.72	-43.4	-47.43	-64.93	-	-65.56	-60.44	-57.49	-65.33	-76.73	-93.02	-94.62	-92.15	-98.06	-95.68	-104	-	-	-	-	-	-	-
Change	-	41.29%	9.28%	36.91%	-100%	-	-7.8%	-4.89%	13.63%	17.45%	21.23%	1.73%	-2.61%	6.41%	-2.44%	-8.7%	100%	-	-	-	-	-	-
Net income ¹	-30.72	-43.4	-47.43	-64.93	-55.98	-65.56	-60.44	-57.49	-65.33	-76.73	-93.02	-93	-91.37	-97.54	-95.84	-126.4	-162.4	-164.7	-151.6	-156	-	-	-
Change	-	41.29%	9.28%	36.91%	-13.79%	17.12%	-7.8%	-4.89%	13.63%	17.45%	21.23%	-0.02%	-1.75%	6.75%	-1.74%	-31.88%	-28.52%	-1.39%	7.98%	-2.9%	100%	-	-
Announcement Date	12/05/21	13/08/21	10/11/21	23/03/22	10/05/22	09/08/22	08/11/22	27/02/23	08/05/23	08/08/23	09/11/23	27/02/24	09/05/24	08/08/24	06/11/24	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Recursion Pharmaceuticals, Inc.

balance-sheet-analysis-chart RECURSION-PHARMACEUTICALS

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-516	-543	-390	-358	-269	-248
Change	-	-	-205.23%	-171.82%	-191.7%	-175.14%	-192.19%
Announcement Date	03/03/21	23/03/22	27/02/23	27/02/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Recursion Pharmaceuticals, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026
CAPEX ¹	39.8	37.06	11.96	13	20.3	21.3
Change	-	-6.88%	-67.74%	8.74%	56.15%	4.93%
Free Cash Flow (FCF) ¹	-198.4	-120.6	-299.7	-311	-365	-221
Change	-	-39.23%	148.57%	3.76%	17.36%	-39.45%
Announcement Date	23/03/22	27/02/23	27/02/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Recursion Pharmaceuticals, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	-	-1,713.2%	-587.23%	-730.58%	-587.07%	-677.11%	-518.4%
EBIT Margin (%)	-	-1,795.79%	-616.74%	-785.33%	-586.75%	-659.22%	-457.5%
EBT Margin (%)	-	-1,832.18%	-601.05%	-745.1%	-560.01%	-636.78%	-348.94%
Net margin (%)	-2,196.01%	-1,832.18%	-601.05%	-735.99%	-587.46%	-655.57%	-348.94%
FCF margin (%)	-	-1,949.42%	-302.65%	-672.43%	-444.29%	-480.21%	-222.23%
FCF / Net Income (%)	-	106.4%	50.35%	91.36%	75.63%	73.25%	63.69%
Profitability
ROA	-	-41.03%	-36.52%	-48.42%	-63.6%	-86.7%	-63.7%
ROE	-	-110.79%	-46.56%	-69.12%	-100.55%	-149.44%	-187.02%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	391.02%	93.01%	26.82%	18.57%	26.71%	21.42%
CAPEX / EBITDA (%)	-	-22.82%	-15.84%	-3.67%	-3.16%	-3.94%	-4.13%
CAPEX / FCF (%)	-	-20.06%	-30.73%	-3.99%	-4.18%	-5.56%	-9.64%
Items per share
Cash flow per share ¹	-	-1.265	-0.4758	-1.384	-1.202	-0.9254	-
Change	-	-	-62.4%	190.98%	-13.16%	-23.03%	-
Dividend per Share ¹	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-
Book Value Per Share ¹	-	3.189	2.768	1.982	1.67	0.895	0.6
Change	-	-	-13.21%	-28.38%	-15.75%	-46.41%	-32.96%
EPS ¹	-5.99	-1.49	-1.36	-1.58	-1.598	-1.715	-1.165
Change	-	-75.13%	-8.72%	16.18%	1.16%	7.3%	-32.07%
Nbr of stocks (in thousands)	-	168,993	189,556	216,623	286,838	286,838	286,838
Announcement Date	03/03/21	23/03/22	27/02/23	27/02/24	-	-	-